Italia markets closed

Novartis AG (0K9E.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a portafoglio
80,67-1,17 (-1,43%)
Alla chiusura: 5:55PM GMT
Schermo intero
Chiusura precedente81,84
Aperto81,12
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno80,56 - 81,16
Intervallo di 52 settimane80,56 - 81,16
Volume44
Media VolumeN/D
Capitalizzazione183,08B
Beta (5 anni mensile)0,53
Rapporto PE (ttm)18,63
EPS (ttm)4,33
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio

    New longer-term efficacy and safety data from pivotal Phase III ASCEMBL study for recently US-approved Scemblix® (asciminib) in patients with PH+ CML-CPEarly findings from YTB323 and PHE885 CAR-T cell therapies highlight the progress in developing the next generation T-Charge™ Platform Final analysis from Phase Ib study evaluating efficacy and safety of sabatolimab (MBG453) in combination with HMAs in patients with very high/high-risk MDS and AML 12-month data from Phase II study of iptacopan (L

  • GlobeNewswire

    Novartis to sell its Roche stake in a bilateral transaction to Roche

    Ad hoc announcement pursuant to Art. 53 LR Novartis and Roche agree a bilateral transaction for the sale of Roche bearer shares held by Novartis for a total consideration of USD 20.7 billion Price of USD 388.99 per share (CHF 356.93 per share) reflects the volume-weighted average price of the Roche non-voting equity certificates (Genussschein) over the last 20 trading days ending on November 2, 2021 Monetization consistent with Novartis strategy as a focused medicines company Use of proceeds wil

  • GlobeNewswire

    FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia

    Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine kinase inhibitor (TKI) treatments1In the pivotal Phase III ASCEMBL trial, Scemblix demonstrated significant and clinically meaningful superiority in major molecular response (MMR) rate vs. Bosulif®* (bosutinib) (25% vs. 13%) at 24 weeks, and more -than -three times lower discontinuation rates due to side